

15 December 2017

ePAT Technologies Limited (**ASX: EPT**)
ABN 21 146 035 127
Suite 401, 35 Lime Street, Sydney, NSW, 2000
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008
Phone +61 8 9388 8290
ianhobson@bigpond.com

ePAT Technologies Ltd company name change to PainChek Ltd.

Today the Company lodged a notice of meeting to seek shareholder approval to change the Company name to PainChek Ltd. There are a number of key reasons for the change:

- PainChek is now a registered trademark in Australia and the company has priority trademark filing dates for PainChek in Europe, US, China and Japan thereby providing a consistent brand in each of these markets within our field of use as we globalize the business.
- PainChek is a brand that clearly communicates what we do and is easily understandable in international markets. We want to ensure we are recognized and remembered as the leading pain assessment technology so consistency and repetition in the company name, the product brand and the visualization of both is key to building a strategic brand advantage.
- As a company we will be focused on developing a range of pain assessment tools for multiple market segments for the for-seeable future. These are very large and relatively untapped global market opportunities.
- We own the PainChek domain name painchek.com and the local PainChek domains in each of these countries.


“Getting our global branding and naming strategy aligned at this early stage is critical to the business and our customers have already endorsed the PainChek product brand. The consistency and repetition of the PainChek logo and visual language across all touch points will help people remember us and associate the look and feel of the company and the product” said CEO Philip Daffas.

“We can see many successful global brands take this approach including Facebook, Uber and Tesla and in the healthcare space I can reflect on my own personal experience working with Cochlear. In each instance the product name reinforces the company name and vice versa and this helps create the global competitive advantage” added Daffas.


PCK has been reserved as the Company’s proposed ticker code with the ASX.

The PainChek™ Technology:

PainChek™ uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain.



PainChek™ artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain



PainChek™ six domains of pain assessment that calculates pain severity score

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured to calculate a pain severity score. Due to its speed, ease of use and it's reproducibility, PainChek™ will be able to be used to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management.

PainChek™ will be rolled out globally in two phases: first, PainChek™ which is designed for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek™ for Children who have not yet learnt to speak.

For further information contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290

Philip Daffas
Managing Director
Tel: +61 406-537-235